

Jasper Tromp MD, Ph.D

Assistant professor of Public Health, National University of Singapore/director of
Cardiovascular clinical trials data management center at National Heart Centre
Singapore

Date of Birth: January 3rd, 1988

Place of Birth: Groningen, the Netherlands

Nationality: Dutch

jtromp@gmail.com

+31 (0) 6 2386 2386

Profile

Physician and clinical epidemiologist with a strong interest in treatment and prevention of heart failure. Degrees in both medicine and international relations. >50 publications accepted/published, including publications in, Lancet Global Health, Circulation, European Heart Journal and Journal of the American College of Cardiology (All IF >20). I am interested in preventing and treating cardiovascular disease in low- and middle-income countries in Southeast and South Asia compared to Western Europe, on which I have published in Lancet, Lancet Global Health, British Medical Journal, European Journal of Heart Failure Circulation.

Education

- 2018 **Ph.D. in Medicine**, University of Groningen
Supervisors: Prof. dr. P. van der Meer and Prof. Dr. A.A. Voors
Committee: Prof. dr. H.P. Brunner de la Rocca; Prof. dr. W.H van Gilst;
Prof. dr. S.J.L Bakker

Dissertation: *Biomarkers and personalized medicine in heart failure*
Distinction: *Cum Laude*.
- 2016 **Medical Doctor (MD)**, University of Groningen
Visiting fellowship at the department of public health, Osaka University, Japan (2015)
- 2012 **BA International relations and International organizations**, University of Groningen
Exchange student at University of Osaka, Japan
Thesis on World Health Organization policy in addressing tuberculosis vaccination in Nigeria
- 2012 **BSc in Medicine**, University of Groningen

Editorial and Reviewer experience

- 2021-Present **Editor PLOS Global Public Health**
- 2020-Present **Section Editor 'comorbidities' for Current Heart Failure Reports**
- Reviews I have provided invited reviews for Lancet, Cell, Circulation, European Heart Journal, Circulation, Journal of the American College of Cardiology, European Journal of Heart Failure, Journal of the American College of Cardiology: Heart Failure, Circulation: Heart Failure and others.

Experience

- 2021-Present **Assistant Professor in Public Health (tenure track)**, Saw Swee Hock School of Public Health, National University Singapore. Epidemiology domain
- 2017-Present **Director**, Cardiovascular clinical trials data management centre (CVCT-DMC), National Heart Centre Singapore (NHCS), Singapore
- Established and currently co-directing the clinical trials data management centre (CVCT-DMC) at National Heart Centre Singapore. We manage and analyze several large scale registries and clinical trials to produce real-world evidence on risk factors for cardiovascular disease and heart failure in Asia.
- Hired and trained (bio-)statisticians to support evidence generation for industry-based collaborations
- 2018-2020 **Post-doctoral Research Fellow**, Duke-National University of Singapore and National Heart Centre Singapore (NHCS), Singapore
- Invited international speaker at several regional and international conferences on cardiovascular disease in low- and middle- income countries in Asia, the United States and Europe
- Research focus area: epidemiology of cardiovascular disease and heart failure in low- and middle-income countries in Asia
- Directly supervising (co-promotor) of 3 PhD students and one statistician
- Supervised >10 bachelor and master theses
- Supported grant writing, totalling over> USD 1.000.000 in extramural funding
- 2017-2020 **Post-doctoral Research Fellow**, University Medical Centre Groningen (UMCG), the Netherlands

Skills

- Quantitative analyses* Stata [8 years], R [4 years], Python [2years]
I have considerable experience analyzing large datasets using statistical and machine learning techniques in Stata, R and Python. Experience with survival, competing risk, propensity score matching, inverse probability weight and advanced variable selection methods.
- Machine learning using R and Python* Keras, Scikit Learn, TensorFlow to analyze large datasets using supervised and unsupervised analyses, including deep learning and cluster analyses.
- Project-based collaboration* I have experience in 50+ projects with researchers and clinicians from Harvard, Imperial College, University of Glasgow, Northwestern.

Additional activities

- 2019-Present **Member of the executive committee of EMPULSE trial**
A member of the executive committee of phase three EMPULSE trial, which tests the efficacy of SGLT-2 inhibitors in acute heart failure.
- 2017-Present **Scientific advisor US2.ai**
I am a scientific advisor and consultant to AI-startup Us2.ai, which uses artificial intelligence and deep learning to automate echocardiography.

Honours and Awards

- 2020 **World Heart Federation Emerging Leader**
Selected as part of the 2020 'Emerging Leader Programme' from the World Heart Federation. Each year, through a competitive process, 25 Emerging Leaders are selected. These are outstanding individuals who have demonstrated long-term promise through their early careers, and creativity and passion for improving cardiovascular health and preventing CVD
- 2019, 2020, 2021 **Invited expert, International Biomarker Workshop**
The international biomarker workshop brings together top experts (<30) on biomarkers in heart failure in a yearly meeting in Cannes.
- 2019 **Representative at the Global Young Scientist summit**
The Global Young Scientist summit is a gathering of young scientists and researchers worldwide with eminent international science and technology leaders in Singapore. I was selected as the SingHealth hospital cluster network representative to attend.
- 2019 **Invitee European Society of Cardiology Heart Failure Association workshop for heart failure with preserved ejection fraction**
I was invited to participate in the European Society of Cardiology Heart Failure Association (ESC-HFA) workshop on heart failure with preserved ejection fraction. The workshop consists of ten selected experts in heart failure with preserved ejection fraction who come together and determine the new research roadmap for heart failure with preserved ejection fraction on behalf of the ESC-HFA. The workshop results will be summarized in a position paper on behalf of the ESC.
- 2018 **Paul Dudley White International Scholar at the American Heart Association Scientific Sessions**
Award for best abstract from Singapore at the American Heart Association Scientific Sessions 2018.

Scientific publications (Selection 10 out of 66)

- 1 Post-discharge prognosis of patients hospitalized for heart failure according to world-region and national levels of income and income-disparity: the REPORT-HF registry.
Tromp J; Bamadhaj S; Cleland JGF; Angermann CE; Dahlstrom U; Tay WT; Dickstein K; Ertl G; Hassanein H; Hu D; Perrone SV; Ghadanfar M; Schweizer A; Oberfell A; Lam CSP; Filippatos G; Collins SP.
Lancet Glob Health. 2020 Mar;8(3): e411-e422
First report on the prevalence of risk factors and 1-year mortality among patients with acute heart failure from a global registry (>18.000 participants) from low- middle- and high- income countries.
- 2 Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng THK, **Tromp J**, Tay WT, Anand IS, Ouwerkerk W, Chopra V, Wander GS, Yap J, MacDonald MR, Xu CF, Chia YMF, Shimizu W, Richards AM, Voors AA, Lam CSP.
Lancet Glob Health. 2018 Sep;6(9):e1008-e1018
Seminal report on underusage of guideline directed medication for patients with heart failure across low- and middle- income countries in Asia. Accompanied by an invited editorial.
- 3 Sex differences in optimal doses of heart failure medication.
Santema BT, Ouwerkerk W, **Tromp J**, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP, Voors AA.
Lancet. 2019 Aug 22. pii: S0140-6736(19)31792-1.
Report on the underuse and effects of heart failure medication in women compared to men in high, middle and low income countries. Accompanied by an invited editorial.
- 4 Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry
Tromp J, Tay WT, Ouwerkerk W, Teng THK, Yap JL, MacDonald MR, Leineweber K, McMurray JJV, Zile MR, Anand IS, Lam CSP.
PLOS Medicine. 2018 Mar; 15(3): e1002541.
Study investigating the prevalence of multimorbidity profiles identified using latent class analyses in 11 Asian regions from the ASIAN-HF registry.
- 5 Heart failure with preserved ejection fraction in Asia.
Tromp J, Teng THK, Tay WT, Hung CL, Narashimhan C, Shimizu W, Park SW, Liew HB, Ngarmukos TH, Reyes EB, Siswanto BB, Yu CM, Zhang S, Yap J, MacDonald MR, Leineweber K, Richards AM, Zile MR, Anand IS, Lam CSP.
Eur J Heart Fail. 2018 Aug 16. doi: 10.1002/ejhf.1227
First report on non-communicable risk factors among patients with heart failure with a preserved ejection fraction across country income levels in Asia. Accompanied by an invited editorial.
- 6 Heart Failure with a Preserved Ejection Fraction in the Young
Tromp J, MacDonald MR, Tay WT, Teng THK, Hung CL, Narasimhan C, Shimizu W, Ling LH, Ng TP, Yap J, McMurray JJV, Zile MR, Anand IS, Lam CSP
Circulation. 2018 Dec 11;138(24):2763-2773
Report on age-related differences in the prevalence of non-communicable risk factors and outcomes among patients with heart failure from Asia. Accompanied by an invited editorial.

- 7 Microvascular Disease prevalence differs in Patients with Diabetes and Heart Failure with a Preserved versus Reduced Ejection Fraction.
Tromp J, Lim SL, Tay WT, Teng THK, Chandramouli C, Yap J, MacDonald MR, Ling LL, Sattar N, McMurray JJV, Richards AM, Anand I, Lam CSP.
Diabetes Care. 2019 Sep;42(9):1792-1799
Prevalence and association with heart failure of microvascular disease in diabetics from Asia.
- 8 Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Kober L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV.
J Am Coll Cardiol. 2019 Aug 6;74(5):601-612
Differences in age related profiles and prevalence of non-communicable risk factors among patients with heart failure from a global representative cohort. Accompanied by an invited editorial.
- 9 Heart Failure around the world.
Tromp J; Fereirra JP; Janwanishstaporn S; Shah M; Greenberg M; Zannad F; Lam CSP.
Eur J Heart Fail. 2019 Aug 16
Invited review on the characteristics and epidemiology of heart failure around the world, with a specific focus on heart failure care in low- and middle income countries.
- 10 Universal Healthcare but not Universal Access?
Tromp J; Collins SP
Eur J Prev Cardiol 2020, 27 (1), 75-78
Invited editorial commenting on the impact of social determinants on mortality of patients with heart failure.

Scientific publications (complete list)**Journal articles**

- 1 Fibrosis Marker Syndecan-1 and Outcome in Patients with Heart Failure with Reduced and Preserved Ejection Fraction
Tromp J, van der Pol A, Klip IT, de Boer RA, Jaarsma T, van Gilst WH, Voors AA, van Veldhuisen DJ, van der Meer P.
Circ Heart Fail. 2014 May;7(3):457-62
- 2 Acute heart failure in the young: Clinical characteristics and biomarker profiles
Tromp J, Meyer S, Mentz RJ, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P.
Int J Cardiol. 2016 Oct 15; 221:1067-72
- 3 Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials)
Tromp J, Ter Maaten JM, Damman K, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P.
Am J Cardiol. 2017 Jan 15; 119(2):290-296
- 4 Biomarker Profiles in Heart Failure Patients with Preserved and Reduced Ejection Fraction
Tromp J, Khan MA, Klip IT, Meyer S, de Boer RA, Jaarsma T, Hillege H, van Veldhuisen DJ, van der Meer P, Voors AA.
J Am Heart Assoc. 2017 Mar 30;6(4)
- 5 Biomarker Profiles of Acute Heart Failure Patients with a Mid-Range Ejection Fraction
Tromp J, Khan MAF, Mentz RJ, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, Van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P.
JACC Heart Fail. 2017 Jul;5(7):507-517
- 6 A network analysis to compare biomarker profiles in patients with and without Diabetes Mellitus in acute heart failure
Sharma A, Demissei BG, **Tromp J**, Hillege HL,3, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Ezekowitz JA, Khan MAF, Voors AA.
Eur J Heart Fail. 2017 Oct;19(10):1310-1320
- 7 Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH
Van der Pol A, Gil A, Silljé HHW, **Tromp J**, Ovchinnikova ES, Vreeswijk-Baudoin I, Hoes M, Domian IJ, van de Sluis B, van Deursen JM, Voors AA, van Veldhuisen DJ, van Gilst WH, Berezhikov E, van der Harst P, de Boer RA, Bischoff R, van der Meer P.
Sci Transl Med. 2017 Nov 8;9(415)
- 8 Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro B-Type Natriuretic Peptide

- Klaassen SHC, **Tromp J**, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, van Veldhuisen DJ, Hazenberg BPC.
Am J Cardiol. 2018 Jan 1;121(1):107-112
- 9 Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF
Beusekamp J, **Tromp J**¹, van der Wal HH, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwindermand AH, Rossignol P, Zannad F, Voors AA, van der Meer P.
Eur J Heart Fail. 2018 May;20(5):923-930
- 10 Prevalence, clinical correlates and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction
Goh VJ, **Tromp J**, Teng THK, Tay WT, van der Meer P, Ling LH, Siswanto BB, Hung CL, Shimizu WT, Zhang S, Narasimhan C, Yu CM, Park SW, Ngarmukos T, Liew HB, Reyers EB, Yap J, MacDonald MR, Richards AM, Anand IS, Lam CSP.
ESC Heart Fail. 2018 Aug;5(4):570-578
- 11 Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry
Tromp J, Tay WT, Ouwerkerk W, Teng THK, Yap JL, MacDonald MR, Leineweber K, McMurray JJV, Zile MR, Anand IS, Lam CSP.
PLoS Med. 2018 Mar 27;15(3): e1002541
- 12 N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure
Tromp J, Richards AM, Tay WT, Teng THK, Yeo DPS, Sim D, Jaufeerally F, Leong G, Ong HY, Ling LH, van Veldhuisen DJ, Jaarsma T, Voors AA, van der Meer P, de Boer RA, Lam CSP
ESC Heart Fail. 2018 Apr;5(2):279-287
- 13 Data-Driven Approach to Identify Subgroups of Heart Failure with Reduced Ejection Fraction Patients with Different Prognoses and Aldosterone Antagonist Response Patterns
Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, Ahmad T, **Tromp J**, Rossignol P, Zannad F.
Circ Heart Fail. 2018 Jul;11(7):e004926
- 14 OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.
Van der Pol A, Gil A, **Tromp J**, Sillje HHW, van Veldhuisen DJ, Voors AA, Hoendermis ES, Schouten M, de Boer RA, Bischoff R, van der Meer P.
Cardiovasc Res. 2018 Dec 1;114(14):1871-1882
- 15 Heart failure with preserved ejection fraction in Asia
Tromp J, Teng THK, Tay WT, Hung CL, Narashimhan C, Shimizu W, Park SW, Liew HB, Ngarmukos TH, Reyes EB, Siswanto BB, Yu CM, Zhang S, Yap J, MacDonald MR, Leineweber K, Richards AM, Zile MR, Anand IS, Lam CSP.
Eur J Heart Fail. 2019 Jan;21(1):23-36

¹ Co-primary author

- 16 Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study
Teng THK, **Tromp J**, Tay WT, Anand IS, Ouwerkerk W, Chopra V, Wander GS, Yap J, MacDonald MR, Xu CF, Chia YMF, Shimizu W, Richards AM, Voors AA, Lam CSP.
Lancet Glob Health. 2018 Sep;6(9):e1008-e1018
- 17 Identifying Pathophysiological Mechanisms in Heart Failure with Reduced Versus Preserved Ejection Fraction
Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA.
J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090
- 18 Renal Function and Exercise Training in Ambulatory Heart Failure Patients with a Reduced Ejection Fraction.
Ambrosy AP, Mudler H, Coles A, Kraus WE, Lam CSP, McCullough PA, Pina I, **Tromp J**, Whellan DJ, O'Connor CM, Mentz RJ.
Am J Cardiol. 2018 Sep 15;122(6):999-1007
- 19 Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
Ferreira JP, Mordi I, Gregson J, Ter Maaten J, **Tromp J**, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Lang CC, Voors AA, Zannad F.
Eur J Heart Fail. 2019 Jan;21(1):112-120
- 20 Heart Failure with a Preserved Ejection Fraction in the Young
Tromp J, MacDonald MR, Tay WT, Teng THK, Hung CL, Narasimhan C, Shimizu W, Ling LH, Ng TP, Yap J, McMurray JJV, Zile MR, Anand IS, Lam CSP
Circulation. 2018 Dec 11;138(24):2763-2773
- 21 Novel Endotypes in Heart Failure: Effects on Guideline-Directed Medical Therapy
Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.
Eur Heart J. 2018 Dec 21;39(48):4269-4276
- 22 Impact of diabetes and sex in HF rEF patients from the ASIAN-HF registry
Chandramouli C, Teng THK, Tay WT, Yap J, MacDonald MR, **Tromp J**, Yan L, Siswanto BB, Reyes EB, Ngarmukos T, Yu CM, Hung CL, Anand IS, Richards AM, Ling HL, Regensteiner JG, Lam CSP.
Eur J Heart Fail. 2019 Mar;21(3):297-307
- 23 Association of Diabetes Mellitus on Cardiac Remodelling, Quality of Life, and Clinical Outcomes in Heart Failure with Reduced and Preserved Ejection Fraction
Yap J, Tay WT, Teng THK, Anand IS, Richards AM, Ling LH, MacDonald MR, Chandramouli M, **Tromp J**, Siswanto BB, Zile MR, McMurray JJV, Lam CSP.
J Am Heart Assoc. 2019 Sep 3;8(17):e013114
- 24 Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus.
Chia YMF, Teng THK, Tay WT, Anand IS, MacDonald MR, Yap J, Chandramouli C, Richards AM, **Tromp J**, Ouwerkerk W, Ling LH, Lam CSP.

Eur J Heart Fail. 2019 May;21(5):685-688

- 25 Late Breast-Cancer Survivors treated with Chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls.
Tromp J, Boerman LM, Maas SWMC, Maduro JH, Hummel YM, Berger MY, de Bock GH, Gietema JA, Berendsen AJ, van der Meer P.
Eur J Heart Fail. 2020 Feb 20. [Epub ahead of print]
- 26 Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: Outcomes in the ASIAN-HF registry.
 MacDonald MR, Tay WT, Teng THK, Anand I, Ling LH, Yap JLL, **Tromp J**, Wander GS, Naik AN, Ngarmukos T, Richards AM, Lam CSP.
J Am Heart Assoc. 2020 Jan 7;9(1): e012199
- 27 The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study.
 Markousis-Mavrogenis G, **Tromp J**, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, Voors AA, van der Meer P.
Eur J Heart Fail. 2019 Aug;21(8):965-973
- 28 Microvascular Disease prevalence differs in Patients with Diabetes and Heart Failure with a Preserved versus Reduced Ejection Fraction.
Tromp J, Lim SL, Tay WT, Teng THK, Chandramouli C, Yap J, MacDonald MR, Ling LL, Sattar N, McMurray JJV, Richards AM, Anand I, Lam CSP.
Diabetes Care. 2019 Sep;42(9):1792-1799
- 29 Age-Related Characteristics and Outcomes of Patients with Heart Failure with Preserved Ejection Fraction.
Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Kober L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV.
J Am Coll Cardiol. 2019 Aug 6;74(5):601-612
- 30 Selenium and outcome in heart failure.
 Bomer N, Grote Beverborg N, Hoes MF, Streng K, Vermeer M, Dokter M, Ijmker J, **Tromp J**, van Veldhuisen DJ, Touw DJ, Voors AA, van der Meer P.
Eur J Heart Fail. 2019 Dec 6. [Epub ahead of print]
- 31 Sex differences in optimal doses of heart failure medication.
 Santema BT, Ouwerkerk W, **Tromp J**, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP, Voors AA.
Lancet. 2019 Oct 5;394(10205):1254-1263
- 32 Role of Cathepsin D in the Pathophysiology of Heart Failure and its Potentially Beneficial Properties: a translational approach.
 Hoes MFGA, **Tromp J**², Ouwerkerk W, Samani NJ, Ng LL, Lang CC, van der Harst P, Hillege H, Anker S, van Veldhuisen DJ, Voors AA, van der Meer P.
Eur J Heart Fail. 2019 Dec 3. [Epub ahead of print]

² Co-primary author

- 33 Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction.
Tromp J; Hage C; Ouwerkerk W; Sanders-van Wijk S; Svedlund S; Saraste A; Faxen UL; Fermer ML; Gan LM; Lund LH; Shah SJ; Lam CSP.
Circulation. 2019 Oct 15;140(16):1359-1361
- 34 Distinct Pathological Pathways in Heart Failure Patients with Diabetes.
Tromp J; Voors AA, Sharma A, Ferreira JP, Ouwerkerk W, Hillege HL, Gomez KA, Lang CC, Ng LL, van der Harst P, van Veldhuisen DJ, van der Meer P, Lam CSP, Zannad F, Sama IE.
JACC Heart Fail. 2020 Mar;8(3):234-242
- 35 Hyperkalemia and treatment with RAAS-inhibitors during acute heart failure hospitalizations and their association with mortality.
Beusekamp JC, **Tromp J**, Cleland JGF, Givertz MM, Metra M, O'Connor C, Teerlink JR, Ponikowski P, van Veldhuisen DJ, Voors AA, van der Meer P.
JACC Heart Fail. 2019 Nov;7(11):970-979
- 36 Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study.
Chandramouli C; Tay WT; Bamadhaj NB; **Tromp J**; Teng THK; Yap JL; MacDonald MR; Hung CL; Streng K; Naik A; Wander GS; Sawhney J; Ling LH; Richards AM; Anand IS; Voors AA; Lam CSP.
PLoS Med. 2019 Sep 24;16(9):e1002916
- 37 Potassium abnormalities in patients with heart failure from 11 Asian regions: Insights from the ASIAN-HF registry.
Beusekamp JC; Teng THK; Tay WT; Ouwerkerk W; Richards AM; Anand IS; van der Meer P; Voors AA; Lam CSP; **Tromp J**.
Eur J Heart Fail. 2020 Apr;22(4):751-754
- 38 The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
Santema BT; Chan MMY; **Tromp J**; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA.
Clin Res Cardiol. 2020 Mar;109(3):331-338
- 39 Concentric versus eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
Nauta JF; Hummel JM; **Tromp J**; Ouwerkerk W; van der Meer P; Jin X; Lam CSP; Bax JJ; Metra M; Samani NJ; Ponikowski P; Dickstein K; Anker SD; Zannad F; Filippatos G; van Veldhuisen DJ; van Melle JP; Voors AA.
Eur J Heart Fail. 2019 Nov 11. [Epub ahead of print]
- 40 Cardiovascular and Non-Cardiovascular death distinction: the utility of Troponin beyond NT-proBNP. Findings from the BIoSTAT-CHF study
Ferreira JP; Ouwerkerk W; **Tromp J**; Ng LL; Dickstein K; Voors AA; Zannad F.
Eur J Heart Fail. 2020 Jan;22(1):81-89
- 41 A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure

Sama IE; Woolley RJ; Nauta JF; Romaine SPR; **Tromp J**; ter Maaten JM; van der Meer P; Lam CSP; Samani NJ; Ng LL; Metra M; Dickstein K; Anker SD; Zannad F; Lang CC; van Veldhuisen DJ; Hillege HL; Voors AA.

Eur J Heart Fail. 2020 Apr 3. [Epub ahead of print]

- 42 Post-discharge prognosis of patients hospitalized for heart failure according to world-region and national levels of income and income-disparity: the REPORT-HF registry.
Tromp J; Bamadhaj S; Cleland JGF; Angermann CE; Dahlstrom U; Tay WT; Dickstein K; Ertl G; Hassanein H; Hu D; Perrone SV; Ghadanfar M; Schweizer A; Oberfell A; Lam CSP; Filippatos G; Collins SP.
Lancet Glob Health. 2020 Mar;8(3):e411-e422
- 43 Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction.
Teng THK; Cooper L; Tay WT; Luo N; Sharma A; Whellan D; Anand IS; Pina IL; **Tromp J**; Richards AM; Kraus W; O'Connor C; Mentz RJ; Lam CSP.
Eur J Heart Fail. 2020 Apr;22(4):754-758
- 44 Ethnic differences in atrial fibrillation among patients with heart failure in Asia
Tan ESJ; Goh V; Santema BT; Tay WT; Teng THK; Yap J; **Tromp J**; Hung CL; Chopra V; Anand IS; MacDonald MR; Ling LH; van Gelder IC; Rienstra M; Voors AA; Richards AM; Lam CSP.
ESC Heart Fail. 2020 May 8. 2020 Aug;7(4):1419-1429
- 45 Heart failure with preserved ejection fraction diagnostic scores in an Asian population.
Ouwkerk W; **Tromp J**²; Jin X; Jaufeerally F; Poh DS; Leong KTG; Ong HY; Ling HL; Loh SY; Sim D; Lee D; Soon D; Chin C; Richards AM; Lam CSP.
Eur J Heart Fail. 2020 Sep;22(9):1737-1739.
- 46 The Association of Conventionally Medicated Systolic and Diastolic Blood Pressure Level and Mortality from Cardiovascular Disease: Is the Lower the Better in High Stroke Population?
Sakaniwa R; **Tromp J**²; Shirai K; Yamagishi K; Tamakoshi A; Iso H.
Clin Res Cardiol. 2020 Jul;109(7):944-948
- 47 Effects of combined RAAS inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: Insights from BIOSTAT-CHF and ASIAN-HF registries
Ouwkerk W; Teng THK; **Tromp J**; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand IS; Richards AM; Voors AA; Lam CSP
Eur J Heart Fail. 2020 Aug;22(8):1472-1482.
- 48 Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study
Sanders-van Wijk S; Tromp J; Beussink-Nelson L; Hage C; Svedlund S; Saraste A; Swat SA; Sanchez C; Njoroge J; Tan RS; Fermer ML; Gan LM; Lund LH; Lam CSP; Shah SJ.
Circulation. 2020 Nov 24;142(21):2029-2044.
- 49 The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure.
Markousis-Mavrogenis G; **Tromp J**; Mentz RJ; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JGF; Givertz MM; van Veldhuisen DJ; Hillege HL; Voors AA; van der Meer P.
J Card Fail. 2021 Jan 23;S1071-9164(21)00011-7

- 50 Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
Tromp J; Ponikowski P; Salsali A; Angermann CE; Biegus J; Blatchford J; Collins SP; Ferreira JP; Grauer G; Kosiborod M; Nassif ME; Psotka MA; Brueckmann M; Teerlink JR; Voors AA.
Eur J Heart Fail. 2021. Feb 2021 Feb 20. doi: 10.1002/ejhf.2137
- 51 Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study
Patel RB; Lam CSP; Svedlund S; Saraste A; Hage C; Tan RS; Beussink-Nelson L; **Tromp J**; Sanchez C; Njoroge J; Swat SA; Faxen UL; Fermer ML; Venkateshavarana A; Gan LM; Lund LH; Shah SJ.
Sci Rep. 2021 Mar 1;11(1):4885
- 52 Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
Woolley RJ; Ceelen D; Ouwerkerk W; **Tromp J**; Figarska SM; Aanker SD; Dickstein K; Filippatos G; Zannad F; Metra M; Leong N; Samani N; van Veldhuisen D; Lang C; Lam CSP; Voors AA.
Eur J Heart Fail. 2021 Mar 2. doi: 10.1002/ejhf.2144.
- 53 Epicardial fat in heart failure with reduced versus preserved ejection fraction
Tromp J; Bryant JA; Jin X; van Woerden G; Asali S; Yiyang H; Ching PCP; Jaufeerally F; Koh SY; Sim D; Lee S; Soon D; Tay WT; Packer M; van Veldhuisen DJ; Chin C; Richards AM; Lam CSP.
Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2156.
- 54 Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia.
Teng THK; Tay WT; Richards AM; Chew TWM; Anand I; Ouwerkerk W; Chandra,ouli C; Huang W; Lawson CA; Kadam UT; Yap J; Lim S; Hung CL; MacDonald MR; Loh SY; Shimizu W; **Tromp J**; Lam CSP.
Circ Cardiovasc Qual Outcomes 2021 Apr;14(4):e006962.
- 55 Age dependent associations of risk factors with heart failure: pooled population based cohort study
Tromp J; Paniagua SMA; Lau ES; Allen NB; Blaha MJ; Gansevoort RT; Hillege HL; Lee DL; Levy D; Vasana RS; van der Harst P; van Gilst W; Larson MG; Shah SJ; de Boer RA; Lam CSP; Ho JE.
BMJ. 2021 Mar 23;372:n461
- 56 Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF
Tromp J; Ouwerkerk W; Cleland JGF; Angermann CE; Dahlstrom U; Teng THK; Bamadhaj S; Ertl G; Hassanein M; Perrone SV; Ghadanfar M; Schweizer A; Obergfell A; G Filippatos; Collins SP; Lam CSP; Dickstein K.
JACC Heart Fail. 2021 Apr 2;S2213-1779(21)00054-8
- 57 Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
Tromp J; Claggett BL; Liu J; Jackson AM; Jhund PS; Kober L; Widimsky J; Boytsov SA; Chopra VK; Anand IS; Ge J; Chen CH; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Rizkala AR; Inubushi-Molessa A; Lefkowitz MP; Shi VC; McMurray JJV; Solomon SD; Lam CSP.
Circ Heart Fail. 2021 Apr;14(4):e007901.
- 58 Effects of SGLT2 inhibition with Empagliflozin on Potassium Handling in Patients with Acute Heart Failure
Beusekamp J; **Tromp J**; Boorsma EM; Heerspink HJL; Damman K; Voors AA; van der Meer P
Eur J Heart Fail. 2021 [Accepted]

Review papers and invited editorials

- 1 Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction
Tromp J; Steggink LC, Gietema J; van der Meer P.
Clin Pharmacol Ther. 2017 Apr;101(4):481-490
- 2 Predicting Heart Failure: One Size Does Not Fit All
Tromp J; van der Meer P
Eur J Heart Fail. 2018 Apr;20(4):674-676
- 3 Heart failure with a mid-range ejection fraction: cause and consequence
Tromp J; Voors AA, Lam CSP
Eur J Heart Fail. 2018 Apr;20(4):660-662
- 4 Hyperkalaemia: Aetiology, Epidemiology and Clinical significance
Tromp J; van der Meer P
Eur Heart J Suppl. 2019 Feb;21(Suppl A): A6-A11
- 5 Heart Failure around the world
Tromp J; Fereirra JP; Janwanishstaporn S; Shah M; Greenberg M; Zannad F; Lam CSP.
Eur J Heart Fail. 2019 Oct;21(10):1187-1196
- 6 Dapagliflozin in Heart Failure: New Frontiers
Tromp J; Collins SP
Eur J Heart Fail. 2019 Nov;21(11):1412-1414
- 7 Universal Healthcare but not Universal Access?
Tromp J; Collins SP
Eur J Prev Cardiol 2020, 27 (1), 75-78
- 8 Heart failure or heart success?
Teramoto K; **Tromp J**; Lam CSP
Cardiovasc Res. 2021 Feb 22; 117(30)e29-e34.